PL1683524T3 - Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny - Google Patents

Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny

Info

Publication number
PL1683524T3
PL1683524T3 PL04818537T PL04818537T PL1683524T3 PL 1683524 T3 PL1683524 T3 PL 1683524T3 PL 04818537 T PL04818537 T PL 04818537T PL 04818537 T PL04818537 T PL 04818537T PL 1683524 T3 PL1683524 T3 PL 1683524T3
Authority
PL
Poland
Prior art keywords
solid dispersion
pharmaceutical preparations
represent
formula
hydrogen atom
Prior art date
Application number
PL04818537T
Other languages
English (en)
Inventor
Hiroyuki Higuchi
Hirokazu Hagio
Kenichi Ogawa
Akira Yabuki
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of PL1683524T3 publication Critical patent/PL1683524T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04818537T 2003-11-14 2004-11-15 Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny PL1683524T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003385501 2003-11-14
PCT/JP2004/016942 WO2005046696A1 (ja) 2003-11-14 2004-11-15 フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
EP04818537A EP1683524B1 (en) 2003-11-14 2004-11-15 Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative

Publications (1)

Publication Number Publication Date
PL1683524T3 true PL1683524T3 (pl) 2011-06-30

Family

ID=34587365

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04818537T PL1683524T3 (pl) 2003-11-14 2004-11-15 Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny

Country Status (12)

Country Link
US (1) US8518441B2 (pl)
EP (1) EP1683524B1 (pl)
JP (1) JP4780522B2 (pl)
KR (2) KR101118930B1 (pl)
CN (2) CN100563658C (pl)
AT (1) ATE495746T1 (pl)
CA (1) CA2546115C (pl)
DE (1) DE602004031144D1 (pl)
DK (1) DK1683524T3 (pl)
ES (1) ES2360064T3 (pl)
PL (1) PL1683524T3 (pl)
WO (1) WO2005046696A1 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070709A1 (en) * 2002-02-20 2003-08-28 Ajinomoto Co.,Inc. Novel phenylalanine derivative
EP1688410B1 (en) 2003-11-27 2014-03-05 Ajinomoto Co., Inc. Crystal of phenylalanine derivative and process for producing the same
JP4703959B2 (ja) * 2003-12-03 2011-06-15 株式会社日立製作所 記憶装置システムおよびそのレプリケーション作成方法
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN101360736A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101057833A (zh) * 2006-04-20 2007-10-24 信越化学工业株式会社 固体分散体制剂
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
AU2007261943B2 (en) 2006-06-22 2012-11-01 Kaneka Corporation Reduced coenzyme Q10-containing composition and method for producing the same
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8343547B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8519120B2 (en) 2006-08-08 2013-08-27 Shin-Etsu Chemical Co., Ltd. Methods for producing a low-substituted hydroxypropylcellulose powder
JP5258224B2 (ja) * 2006-08-08 2013-08-07 信越化学工業株式会社 固体分散体の固形製剤及びその製造方法
EP2103601B1 (en) 2006-11-22 2012-03-14 Ajinomoto Co., Inc. Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
US7718652B2 (en) 2006-12-12 2010-05-18 Wyeth Llc Substituted benzothiadiazinedioxide derivatives and methods of their use
ZA200905094B (en) * 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US20110053942A1 (en) * 2008-02-13 2011-03-03 Dainippon Sumitomo Pharma Co., Ltd. Orally disintegrating tablets
JP5750266B2 (ja) * 2008-02-28 2015-07-15 アッヴィ・インコーポレイテッド 錠剤およびその調製
RS56894B1 (sr) * 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8303868B2 (en) * 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
CN102548542B (zh) * 2009-08-11 2013-11-20 大日本住友制药株式会社 含有两种以上粒子的口腔速崩片
EP2554542B1 (en) * 2010-03-29 2015-10-07 Ajinomoto Co., Inc. Phenylalanine derivative hydrochloride salt crystal
JP5783499B2 (ja) 2010-03-29 2015-09-24 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
BR112017006272A2 (pt) 2014-09-29 2018-03-13 Ea Pharma Co., Ltd. composição farmacêutica para tratar colite ulcerativa.
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP2022171507A (ja) * 2021-04-30 2022-11-11 日本ジェネリック株式会社 安定性に優れたリナグリプチン含有製剤
KR20240046862A (ko) * 2021-08-12 2024-04-11 에이케이아이, 인크. 모발을 위한 부드러운 비-실리콘 향료 제품

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
JPH05310571A (ja) * 1991-07-01 1993-11-22 Ishihara Sangyo Kaisha Ltd 非晶質性ベンゾイルウレア系化合物の抗ガン性医薬組成物
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
JPH07324086A (ja) 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6005069A (en) 1996-12-18 1999-12-21 Donlar Corporation Production of polysuccinimide and derivatives thereof in a sulfur-containing solvent
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
BR9811594A (pt) * 1997-07-31 2000-09-05 Elan Pharm Inc Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
DE69804994D1 (de) 1997-11-03 2002-05-23 Janssen Pharmaceutica Nv Arzneimittel enthaltend lipidsenkende verbindungen
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JPH11246404A (ja) 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6331646B1 (en) * 1998-11-20 2001-12-18 The Nutrasweet Co. Amorphous N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
JP2000281561A (ja) 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
IL152205A0 (en) 2000-04-19 2003-05-29 Fujiswa Pharmaceutical Co Ltd A solid dispersion, pharmaceutical compositions containing the same and methods for the preparation thereof
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
CA2420040C (en) * 2000-08-18 2009-02-03 Ajinomoto Co., Inc. New phenylalanine derivatives
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
WO2002069932A1 (en) 2001-03-05 2002-09-12 Nippon Shinyaku Co., Ltd. Foaming compositions
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
JP4135373B2 (ja) 2002-02-15 2008-08-20 味の素株式会社 光学活性β−フェニルアラニン誘導体の製造方法
EP1595870B1 (en) 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
EP1683525B1 (en) 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
EP1688410B1 (en) 2003-11-27 2014-03-05 Ajinomoto Co., Inc. Crystal of phenylalanine derivative and process for producing the same
BRPI0418026A (pt) * 2003-12-22 2007-04-17 Ajinomoto Kk derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças

Also Published As

Publication number Publication date
CA2546115C (en) 2013-01-08
EP1683524B1 (en) 2011-01-19
CN100563658C (zh) 2009-12-02
EP1683524A1 (en) 2006-07-26
DE602004031144D1 (de) 2011-03-03
KR101118930B1 (ko) 2012-03-14
US8518441B2 (en) 2013-08-27
CN101664411A (zh) 2010-03-10
CN1882346A (zh) 2006-12-20
ATE495746T1 (de) 2011-02-15
KR20060125766A (ko) 2006-12-06
KR20110086886A (ko) 2011-08-01
US20060204572A1 (en) 2006-09-14
ES2360064T3 (es) 2011-05-31
DK1683524T3 (da) 2011-03-14
EP1683524A4 (en) 2010-04-14
WO2005046696A1 (ja) 2005-05-26
JP4780522B2 (ja) 2011-09-28
JPWO2005046696A1 (ja) 2007-05-24
KR101138219B1 (ko) 2012-04-24
CA2546115A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
EP1683524A4 (en) SOLID DISPERSION OR PREPARATION OF MEDICINAL SOLID DISPERSION OF A PHENYLALANINE DERIVATIVE
EP1156045A4 (en) AMID DERIVATIVES AND DRUG COMPOSITIONS
WO2003037862A1 (en) Amide derivatives and drugs
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
GEP20053454B (en) Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof
TR200100300T2 (tr) Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
GEP19991870B (en) Alkyl Amine Derivatives of Substituted Quinoxaline 2,3-Diones as Glutamate Receptor Antagonists
AU1247195A (en) Cyclic amide derivatives as neurokinin a antagonists
WO2002100819A1 (fr) Derives de n-arlyphenylacetamide et compositions medicinales contenant lesdits derives
NO912805L (no) Fremgangsmaate for fremstilling av pyrazolopyridin-forbindelser.
ATE323687T1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
GEP20084300B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
HUT65351A (en) Process for preparing ethanolamine derivatives haring sympathominetic and anti-pollakiuria activity and pharmaceutical compositions containing them as active agent
EP1243268A4 (en) MEDICINAL COMPOSITION
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
EP1193256A8 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
EP1130015A4 (en) Pyridazinone derivatives
ZA921341B (en) 4-((2-benzothiazolyl)methylamino)-a-(3,4-difluorophenoxy) methyl)-1-piperidineethanol.
GEP20063759B (en) Novel Benzothiazine and Benzothiadiazine Derivatives, Method for Preparing Same and Pharmaceutical Compositions Containing Same
EP1209166A4 (en) A-500359 DERIVATIVES
AU2408602A (en) Indole derivatives and use thereof in medicines
CA2451768A1 (en) Peptoid compounds
WO2000024389A3 (en) Benzoquinoline derivatives useful as antibacterial agents
GEP20063757B (en) Novel Benzothiazine and Benzothiadiazine Derivatives, Method for Preparing Same and Pharmaceutical Compositions Containing Same
BG106079A (en) Cyclocarbamate derivatives as progesterone receptor modulators